Cargando…

Genomic Insights into Achromobacter mucicolens IA Antibiotic Resistance

Achromobacter denitrificans is an environmental opportunistic pathogen that is infecting a large number of immunocompromised patients. A more recently identified strain from the historical collection of strains of Achromobacter denitrificans is Achromobacter mucicolens. In hosts with a variety of un...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Asadi, Sura Ali, Al-Kahachi, Rusul Emaduldeen S., Alwattar, Wifaq M. Ali, Bootwala, Jamila, Sabbah, Majeed Arsheed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045304/
https://www.ncbi.nlm.nih.gov/pubmed/35377213
http://dx.doi.org/10.1128/spectrum.01916-21
_version_ 1784695286635954176
author Al-Asadi, Sura Ali
Al-Kahachi, Rusul Emaduldeen S.
Alwattar, Wifaq M. Ali
Bootwala, Jamila
Sabbah, Majeed Arsheed
author_facet Al-Asadi, Sura Ali
Al-Kahachi, Rusul Emaduldeen S.
Alwattar, Wifaq M. Ali
Bootwala, Jamila
Sabbah, Majeed Arsheed
author_sort Al-Asadi, Sura Ali
collection PubMed
description Achromobacter denitrificans is an environmental opportunistic pathogen that is infecting a large number of immunocompromised patients. A more recently identified strain from the historical collection of strains of Achromobacter denitrificans is Achromobacter mucicolens. In hosts with a variety of underlying diseases, Achromobacter spp. can induce a wide spectrum of disorders. Because of the bacterium’s intrinsic genetic constitution and resistance gained over time, antibiotics are challenged to handle A. mucicolens. Due to the fact that A. mucicolens is rare and its taxonomy is not completely understood, it is difficult to define clinical symptoms, acquisition risk factors, and thus the best therapeutic course of action. To help comprehend this intrinsic and acquired resistance, we analyzed the entire genome of the A. mucicolens IA strain and utilized bioinformatics methods to estimate the strain's probable drug resistance profile. In our study, we have isolated and cultured a clinically important A. mucicolens strain and subjected it to antimicrobial susceptibility tests against antibiotics in the Vitek 2 testing system. The strain’s genome sequence as well as an investigation of 27 of its phenotypic traits provides important information regarding this pathogen. The genome of this A. mucicolens IA strain possesses a number of antibiotic resistance genes that code for efflux pump systems and other antibiotic-regulating as well as -modifying enzymes. Our research analysis predicted genes involved in drug resistance, including genes for efflux pump systems, antibiotic efflux, antibiotic inactivation, and antibiotic target alteration. In vitro studies validated the genomic evidence for its ability to exhibit resistance against a wide range of antibiotics. Our investigation paves the way for more research on understanding the functioning of the key discovered genes that contribute toward the pathogenicity of A. mucicolens and hence gives new information and treatment options for this emerging pathogen. IMPORTANCE Achromobacter species are well-known opportunistic human pathogens that can be found in water and soil and most commonly in hospital settings. They thrive in immunocompromised individuals, producing sporadic cases of pneumonia, septicemia, peritonitis, urinary tract infections, and other illnesses. Achromobacter strains are inherently resistant to a wide spectrum of antibiotics, making them difficult to treat promptly. The strain under study, A. mucicolens, was notably resistant to various antibiotics, and the infection could be controlled only after several rounds of prescription medications at different doses. This consumed a lot of time and put the already immunosuppressed leukemic patient through a great ordeal. The study aimed to raise awareness about the importance of the Achromobacter bacterium’s lethality, and doctors should evaluate the bacterium’s potential for resistance before prescribing antibiotics. Sanitation and other precautions should also be implemented in hospitals and other public places.
format Online
Article
Text
id pubmed-9045304
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-90453042022-04-28 Genomic Insights into Achromobacter mucicolens IA Antibiotic Resistance Al-Asadi, Sura Ali Al-Kahachi, Rusul Emaduldeen S. Alwattar, Wifaq M. Ali Bootwala, Jamila Sabbah, Majeed Arsheed Microbiol Spectr Research Article Achromobacter denitrificans is an environmental opportunistic pathogen that is infecting a large number of immunocompromised patients. A more recently identified strain from the historical collection of strains of Achromobacter denitrificans is Achromobacter mucicolens. In hosts with a variety of underlying diseases, Achromobacter spp. can induce a wide spectrum of disorders. Because of the bacterium’s intrinsic genetic constitution and resistance gained over time, antibiotics are challenged to handle A. mucicolens. Due to the fact that A. mucicolens is rare and its taxonomy is not completely understood, it is difficult to define clinical symptoms, acquisition risk factors, and thus the best therapeutic course of action. To help comprehend this intrinsic and acquired resistance, we analyzed the entire genome of the A. mucicolens IA strain and utilized bioinformatics methods to estimate the strain's probable drug resistance profile. In our study, we have isolated and cultured a clinically important A. mucicolens strain and subjected it to antimicrobial susceptibility tests against antibiotics in the Vitek 2 testing system. The strain’s genome sequence as well as an investigation of 27 of its phenotypic traits provides important information regarding this pathogen. The genome of this A. mucicolens IA strain possesses a number of antibiotic resistance genes that code for efflux pump systems and other antibiotic-regulating as well as -modifying enzymes. Our research analysis predicted genes involved in drug resistance, including genes for efflux pump systems, antibiotic efflux, antibiotic inactivation, and antibiotic target alteration. In vitro studies validated the genomic evidence for its ability to exhibit resistance against a wide range of antibiotics. Our investigation paves the way for more research on understanding the functioning of the key discovered genes that contribute toward the pathogenicity of A. mucicolens and hence gives new information and treatment options for this emerging pathogen. IMPORTANCE Achromobacter species are well-known opportunistic human pathogens that can be found in water and soil and most commonly in hospital settings. They thrive in immunocompromised individuals, producing sporadic cases of pneumonia, septicemia, peritonitis, urinary tract infections, and other illnesses. Achromobacter strains are inherently resistant to a wide spectrum of antibiotics, making them difficult to treat promptly. The strain under study, A. mucicolens, was notably resistant to various antibiotics, and the infection could be controlled only after several rounds of prescription medications at different doses. This consumed a lot of time and put the already immunosuppressed leukemic patient through a great ordeal. The study aimed to raise awareness about the importance of the Achromobacter bacterium’s lethality, and doctors should evaluate the bacterium’s potential for resistance before prescribing antibiotics. Sanitation and other precautions should also be implemented in hospitals and other public places. American Society for Microbiology 2022-04-04 /pmc/articles/PMC9045304/ /pubmed/35377213 http://dx.doi.org/10.1128/spectrum.01916-21 Text en Copyright © 2022 Al-Asadi et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Al-Asadi, Sura Ali
Al-Kahachi, Rusul Emaduldeen S.
Alwattar, Wifaq M. Ali
Bootwala, Jamila
Sabbah, Majeed Arsheed
Genomic Insights into Achromobacter mucicolens IA Antibiotic Resistance
title Genomic Insights into Achromobacter mucicolens IA Antibiotic Resistance
title_full Genomic Insights into Achromobacter mucicolens IA Antibiotic Resistance
title_fullStr Genomic Insights into Achromobacter mucicolens IA Antibiotic Resistance
title_full_unstemmed Genomic Insights into Achromobacter mucicolens IA Antibiotic Resistance
title_short Genomic Insights into Achromobacter mucicolens IA Antibiotic Resistance
title_sort genomic insights into achromobacter mucicolens ia antibiotic resistance
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045304/
https://www.ncbi.nlm.nih.gov/pubmed/35377213
http://dx.doi.org/10.1128/spectrum.01916-21
work_keys_str_mv AT alasadisuraali genomicinsightsintoachromobactermucicolensiaantibioticresistance
AT alkahachirusulemaduldeens genomicinsightsintoachromobactermucicolensiaantibioticresistance
AT alwattarwifaqmali genomicinsightsintoachromobactermucicolensiaantibioticresistance
AT bootwalajamila genomicinsightsintoachromobactermucicolensiaantibioticresistance
AT sabbahmajeedarsheed genomicinsightsintoachromobactermucicolensiaantibioticresistance